Recon: US to complete its exit from WHO; Janux, BMS enter $850M deal to develop solid tumor therapy

• Senior CDC official: Loss of measles elimination status in US would be ‘cost of doing business’ (STAT)
• The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain (STAT)
• As FDA raises bar in rare diseases, pivotal moment nears for RegenxBio (STAT)
• Vaccine makers feel a chill as Kennedy's rhetoric becomes reality (Reuters)
• FDA Moves to Tighten Food Label Rules to Warn About Gluten (Bloomberg) (HHS) (Federal Register)
• FDA clears Aidoc tool to detect 14 different conditions from a CT scan (STAT)

• U.S. makes exit from the WHO complete (STAT) (Reuters)
• China-rooted Corxel raises up to $287M for GLP-1 pill with global ambitions (Endpoints)
• Is Europe raising its drug prices? Depends who you ask (Endpoints)
• Hua Medicine plots diabetes drug expansion in China and beyond (Endpoints)
• Greater Involvement Of The European Medicines Agency Could Refocus Devices Sector (MedTech Insight)
• EU Faces Tariff & Trade Deal Woes As Mercosur And US Deals Paused (Pink Sheet)
• Guinea-Bissau says plans for controversial U.S.-funded vaccine study need further review (STAT)

• Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug (Reuters) (Endpoints)
• Amicus reveals it had another suitor before reaching $4.8B sale to BioMarin (STAT)
• Corcept's drug extends patients' lives in key ovarian cancer study (Endpoints)
• BioMarin vets spearhead new biotech with $82M for rare disease drugs (Endpoints)
• Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV (Reuters)
• Many patients may keep off lost pounds after stopping a GLP-1, US data suggests (Reuters)
• Merck unit partners with global health coalition to develop affordable Ebola vaccine (Reuters)
• India's Alivus Lifesciences posts higher third-quarter profit on API boost (Reuters)

• AdvaMed leaders on tariffs, MDUFA and wearables (MedTech Dive)
• Abbott posts Q4 sales below expectations (MedTech Dive)
• ECRI names misuse of AI chatbots as top health tech hazard for 2026 (MedTech Dive)
• J&J’s cardiovascular business boosts medtech growth in 2025 (MedTech Dive)
• Abbott Wins CE Mark For Dual-Ablation Catheter In Increasingly Competitive AFib Ablation Market (MedTech Insight)
• Multiple Injuries, Deaths Linked To Boston Scientific Axios Stent And Delivery System (MedTech Insight)

• What RFK Jr.’s milk mustache says about the historic power of dairy in the U.S. (STAT)
• Recalled tuna accidently shipped to stores in 9 states: How to know if your cans are impacted (The Hill)

• Alabama hospital system would gain monopoly with proposed $450 million deal (STAT)
• A Goldilocks approach to centralization of high-risk pathogen research (STAT)
• Top CDC vaccine adviser questions need for polio shot, other longstanding recommendations (STAT)
• Anthony Letai says NCI is more stable than perceived and is heading for a big year (STAT)
• Health insurance CEOs head to DC (Endpoints)
• After Push To Expand ‘Real-Time’ Application Review Beyond Oncology, STAR Gets No Takers (Pink Sheet)